|
Market Closed -
Canadian Securities Exchange
12:13:48 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 0.005000 CAD | 0.00% |
|
0.00% | -66.67% |
| Market Cap | 671K 480K 428K 396K 359K 45.55M 682K 4.76M 1.89M 23.86M 1.8M 1.76M 75.23M | P/E 2024 |
-1.31x | P/E 2025 | -4.23x |
|---|---|---|---|---|---|
| Enterprise Value | 2.17M 1.55M 1.39M 1.28M 1.16M 147M 2.21M 15.42M 6.1M 77.23M 5.83M 5.7M 243M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
77.22% | Yield 2024 * |
-
| Yield 2025 | - |
Canadian Securities ExchangeCAD
| Markets | Quality | ||
|---|---|---|---|
Canadian Securities Exchange
| PHRX | Delayed | |
OTC Markets
| LMLLF | Delayed | |
|
Deutsche Boerse AG
| G11 | Delayed | |
|
Boerse Muenchen
| G11 | Real-time |
| 3 months | -50.00% | ||
| 6 months | -50.00% | ||
| Current year | -66.67% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0.01 |
| Current year | 0 | | 0.02 |
| 1 year | 0 | | 0.02 |
| 3 years | 0 | | 0.08 |
| 5 years | 0 | | 0.46 |
| 10 years | 0 | | 4.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kyle Appleby
DFI | Director of Finance/CFO | 50 | 2023-10-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul McClory
BRD | Director/Board Member | 82 | 2016-12-19 |
David Kideckel
CHM | Chairman | - | 2024-02-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/14/25 | Other | Chairman | 1,380,000 | 1.2929% | ||
| 5/3/24 | Other | Director | 0 | 0% | ||
| 5/3/24 | Option | Director | 500,000 | 0.5718% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | -50.00% | -85.71% | 478K | |
| -2.54% | +1.75% | +56.75% | +117.82% | 1,165B | |
| -1.42% | +4.16% | +36.73% | +72.42% | 645B | |
| +0.16% | +0.79% | +24.91% | +95.34% | 504B | |
| -0.31% | +2.95% | +39.36% | +63.56% | 380B | |
| -1.34% | +0.06% | +65.81% | +41.49% | 363B | |
| -0.68% | +1.67% | +22.07% | +50.94% | 297B | |
| -1.20% | +0.99% | +2.26% | +22.95% | 269B | |
| -1.79% | +1.20% | +48.41% | +57.55% | 237B | |
| -0.73% | -0.85% | +28.47% | +100.57% | 195B | |
| Average | -0.85% | +2.29% | +27.48% | +53.69% | 405.55B | |
| Weighted average by Cap. | -1.15% | +3.17% | +40.78% | +80.33% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -793K -567K -506K -468K -424K -53.84M -806K -5.63M -2.23M -28.21M -2.13M -2.08M -88.93M | -383K -274K -245K -226K -205K -26.02M -390K -2.72M -1.08M -13.63M -1.03M -1.01M -42.98M |
| Net Debt | 1.27M 911K 813K 751K 681K 86.46M 1.3M 9.04M 3.58M 45.3M 3.42M 3.35M 143M | 1.5M 1.07M 958K 885K 802K 102M 1.53M 10.65M 4.22M 53.37M 4.03M 3.94M 168M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-23 | $0.005000 | 0.00% | 7,000 |
| 26-10-22 | $0.005000 | 0.00% | 5,000 |
| 26-10-21 | $0.005000 | 0.00% | 20,682 |
| 26-10-20 | $0.005000 | 0.00% | 1,035 |
| 26-10-19 | $0.005000 | 0.00% | 3,464 |
- Stock Market
- Stocks
- PHRX Stock
Select your edition
All financial news and data tailored to specific country editions
